Marfan Syndrome Disease

Published Date : Jan 2024
Category : Genetic Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

"Innovating Progress: Unraveling the Mysteries of Marfan Syndrome and Embracing a Future of Hope and Understanding."

Marfan syndrome is a rare genetic disorder that has a distinctive impact on its carriers, affecting different facets of their physical well-being. Marfan syndrome is named for the French pediatrician Antoine Marfan, who initially reported the disorder in 1896. The ailment is typified by a variety of anomalies in connective tissue. This complex network of genetic variations frequently results in unique characteristics that impact the skeletal, cardiovascular, and ocular systems.

According to NIH, around 1 in every 3000 to 5000 individuals are impacted. Race or gender is not a factor in the disease's global spread. It displays varied expression and total penetration. Because of de novo mutations, 25% of cases manifest irregularly. One of the most prevalent single-gene malformation syndromes is MFS.

Marfan syndrome (MFS) is a connective tissue condition caused by a genetic defect. All other bodily tissues and organs are supported, shielded, and given structure by connective tissue. It is brought on by a mutation in a gene that aids in the body's production of a protein that gives connective tissue its elasticity and strength. Marfan syndrome is inherited, however, there are instances where the syndrome develops on its own without any family history.

Serious side effects of Marfan syndrome include aneurysms in the aorta, the major artery that drains blood from the heart. When an aortic aneurysm occurs, the aorta's walls rupture, allowing blood to seep into the empty area left behind.

Defects in or deletions from the fibrillin-1 (FBN1) gene result in Marfan syndrome. Not every individual with a mutation in this gene experiences the syndrome. Certain modifications do not impact the gene's or protein's function, and as a result, they do not result in health issues. Conditions other than Marfan syndrome arise from variations in the FBN1 gene.

Instructions for making (encoding) the fibrillin-1 protein are encoded in the FBN1 gene. The extracellular matrix, a complex substance that envelops and unites all the body's cells, contains fiber-like structures called microfibrils, of which fibrillin-1 is a component.

Between 40 to 54 percent of patients with MFS have mitral valve prolapse (MVP). Since MVP is generic, it receives only 1 point in the systemic score. MVP is more common in women and rises in frequency with age in MFS.

Inheritance of Marfan Syndrome

MFS is an autosomal dominant disorder that is inherited. When a disease is caused by a single aberrant copy of a gene, this is known as a dominant genetic illness. The faulty gene is inherited from one or both parents, or it arises from a novel mutation (gene alteration) in the afflicted person. A novel mutation is responsible for the disease-causing DNA alteration in about 25% of cases with Marfan syndrome. Each pregnancy carries a 50% chance of the faulty gene being passed from the affected parent to the offspring. Both men and women are at equal threat. A novel mutation causing Marfan syndrome increases the likelihood that a person's offspring will also have this gene change and hence have Marfan syndrome.

Sign & Symptoms

The signs and symptoms of Marfan syndrome differ widely throughout individuals. While some people only experience a few minor or isolated symptoms, others experience more significant side effects. Marfan syndrome typically worsens with age in most cases. Some newborns with Marfan syndrome experience severe, quickly progressing problems during infancy, which frequently impact several organ systems at once. Numerous bodily systems, including the heart, blood vessels, skeleton, eyes, lungs, and skin, are impacted by Marfan syndrome.

Symptoms of Marfan syndrome include:

  • tall and thin in stature
  • disproportionately lengthy fingers, arms, and legs
  • a breastbone that is recessed or projected outward.
  • crowding of the teeth and a high, arched palate
  • murmurs in the heart
  • severe nearsightedness
  • a spine that is unusually curved
  • flat feet

Furthermore, underdevelopment of the colored part of the eye (hypoplastic iris), detachment of the nerve-rich membrane (retina) lining the back of the eyes, and unusually flat corneas (the part of the eyes through which light flows) are other difficulties observed in patients with Marfan syndrome.

Diagnostic Analysis

Due to the similarities in signs and symptoms with other connective tissue disorders, Marfan syndrome is difficult for medical professionals to identify. The features and severity of the signs and symptoms of Marfan syndrome vary greatly, even between family members.

Ghent Criteria

Health care providers use the Ghent criteria as a diagnostic tool to help identify Marfan syndrome and distinguish it from other syndromes that present with similar symptoms.

Both major and minor standards are present. Minor criteria are widespread in both populations, while big criteria are indicators that are common in affected persons but unusual in healthy individuals. Two major criterion and one minor criterion must be met by the patient to diagnose Marfan syndrome.

Major requirements include an enlarged aorta, an aortic tear, an eye lens dislocation, history of Marfan syndrome in the family dural ectasia, at least four skeletal issues (such as scoliosis or flat feet).

A few minor requirements are opiates stretches markings, slack joints, elongated, narrow face, elevated and curved palate.

Physical Examination

The objective of the physical examination is to keep an eye out for the symptoms that Marfan syndrome patients often experience in the early stages of the illness. This typically entails listening to the heart in addition to looking for symptoms of the condition, like long, thin limbs, and checking the skin for noticeable stretch marks.

Imaging Test

  • Echocardiogram- Examine the heart for ventricular dilatation or thickening, check for heart valve issues using an echocardiogram, and look for enlargement, dissections (tears), or aneurysms in the aorta.
  • Electrocardiogram- The purpose of an ECG is to measure cardiac rhythm and rate. Temporary electrodes are placed on the limbs and chest during an EKG/ECG to record, monitor, and track the heart's electrical activity, which regulates the heartbeat.
  • MRI Scan- An MRI scan examines the aorta and other blood vessels and looks for dural ectasia by using radio waves and a strong magnetic field to create a detailed image of the inside of the body.

Laboratory Test

  • Eye tests

Slit-lamp test: This examination looks for detached retinas, cataracts, and lens dislocations. For this exam, patients need to use drops to completely dilate their eyes.

Eye pressure test: Doctor uses a specific gadget to touch eyeball and measure the pressure inside to check for glaucoma. Before this examination, numbing eyedrops are typically applied.

  • Genetic test

To confirm the diagnosis of Marfan syndrome, genetic testing is frequently utilized. Family members are examined to see if they are also impacted if a Marfan mutation is discovered. Before beginning a family, if a patient wants to consult a genetic counselor to find out how likely it is that future children will inherit Marfan syndrome.

Diagnostic Market Players

Diagnostic Market Players

Diagnostic Product

Devine Meditech

DME 1250

Gem Optical Instruments Industries


Siemens Healthcare Private Limited


SonoScape Medical Corp

Discovery™ MI

Wipro GE Healthcare Private Limited

GE Discovery MR450

Tentabs Tech Solutions Pvt Ltd


Canon Medical Systems


Hitachi Healthcare


Philips Healthcare


Hologic Inc.


Medtronic plc.


EXELINT International, Co.


APC International, Ltd. (U.S.)


Becton, Dickinson, and Company (BD)



Treatment Analysis

Marfan syndrome has no known cure, although its numerous consequences are avoided with treatment. To do this, patients must be routinely monitored for indications that the disease's damage is escalating.

Those with Marfan syndrome used to frequently pass away at an early age. Many people with Marfan syndrome today anticipate living longer lives thanks to modern therapy and routine monitoring.


  • Beta-blockers: Beta-blockers lessen arterial pressure and increase the heart's capacity to relax while also reducing the heartbeat's force. This stops the aorta from growing larger or slows it down. Starting beta-blocker therapy early is recommended.
  • Angiotensin receptor blockers (ARBs): ARBs are used to treat heart failure and high blood pressure. According to recent clinical research, ARBs, and beta-blockers both contribute to slowing aortic enlargement.

Surgeries & other Procedure

  • Aortic repair: A doctor prescribes surgery to replace a section of the aorta with a synthetic tube if the diameter of the aorta exceeds approximately 2 inches (50 millimeters) or if it is growing quickly. This lessens the chance of a potentially fatal rupture. It is also necessary to replace the aortic valve.
  • Scoliosis Treatment: Consulting with a spine specialist is necessary when there is a substantial degree of scoliosis. In certain situations, bracing and surgery are required.
  • Breastbone Correction: The appearance of a depressed or projecting breastbone is corrected surgically. Insurance does not pay these charges because these procedures are frequently regarded as cosmetic.

Lifestyle & Home Remedies

Patients who have a higher risk of aortic dissection or rupture should refrain from competitive sports and some recreational activities. Elevations in blood pressure, which are typical during exercises like weightlifting, put additional stress on the aorta. In general, less strenuous sports like golf, doubles tennis, bowling, and brisk strolling are safer.

Treatment Market Players

Treatment Market Players

Treatment Product

Aurobindo Pharma Limited


 Lupin Pharmaceuticals, Inc


Sun Pharmaceutical Industries Ltd.


Medichem SA

Toprol XL®

Changzhou Pharmaceutical Factory,


Ipca Laboratories Ltd


Glenmark Pharmaceutical Inc


Abbott laboratories


Medtronic Plc.


Boston Scientific Corp


Artivion inc


Jenavalve technology Inc



Marfan Syndrome Trend

Molecular genetic research on Marfan syndrome and kindred inherited aortic disorders is given top priority by the Center for Marfan Syndrome and Related Aortic Disorders. Research and practice in all facets of cardiac care have increased because of groundbreaking work in cardiovascular surgery. By pushing the frontiers of current understanding, physicians and researchers at the Donald W. Reynolds Cardiovascular Clinical Research Center and the Falk Center for Cardiovascular Research are better able to diagnose and treat patients with Marfan syndrome and other aortic illnesses.

Furthermore, The Marfan Foundation revised its research grant program on August 3, 2021, with the goal of advancing transformative science. The goal of the Marfan Foundation's Research Grant Program is to support researchers studying all facets of hereditary aortic and vascular disorders, including VEDS, EDS, LDS, and Marfan syndrome. With the permission of the board of directors, grants are given out after the Marfan Foundation Scientific Advisory Board evaluates grant proposals.

Clinical trial Assessment

DiseaseLandscape Insights consultancy firm provides valuable support in future market trends on the development of new pharmaceutical products. This support helps to streamline the planning and execution of clinical trials of novel medications and treatments, implement effective patient recruitment strategies, ensure regulatory compliance, and increase the likelihood of successful trial outcomes. 

Phase 3

Artisan Aphakia Lens for the Correction of Aphakia in Children



DiseaseLandscape Insights recognizes the critical importance of understanding disease. DLI's comprehensive services are intended to help the healthcare sector, its professionals, researchers, and other industry participants improve patient outcomes while strengthening and expanding their businesses.

By channeling the power of extensive market research, DLI services provide invaluable insights into the latest advancements, treatment techniques, and emerging trends in the management of Marfan Syndrome. This enables healthcare professionals to make informed decisions, devise targeted strategies, and deliver personalized care to patients.

Moreover, DLI services serve as a catalyst for collaboration and innovation, fostering partnerships among industry stakeholders and researchers to drive advancements in the Marfan Syndrome treatment and prevention market.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape